Treating Patients With Prostate Cancer During COVID-19 Era Poses New Challenges
Monica L. Baskin, PhD, addresses the biggest challenges in treating patients with prostate cancer during the COVID-19 era.
Monica L. Baskin, PhD, professor, Division of Preventive Medicine, vice chair for culture and diversity, Department of Medicine, associate director, Community Outreach and Engagement, O’Neal Comprehensive Cancer Center, The University of Alabama at Birmingham, addresses the biggest challenges in treating patients with prostate cancer during the coronavirus disease 2019 (COVID-19) era.
The biggest challenge is moving beyond the patient’s anxiety of coming into the clinic or getting involved at healthcare facilities due to concerns of COVID-19, according to Baskin. It’s important to balance these concerns with the patient’s ongoing need for treatment.
Baskin notes that many cases in prostate cancer are slow growing, in which case patients can wait for treatment. However, some patients are reluctant to complete screening and treating due to the COVID-19 pandemic. This is a challenge for many physicians, and it is important to move forward with cancer treatment and to do so in a safe manner, Baskin concludes.
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
Conservative Management Is on the Rise in Intermediate-Risk Prostate Cancer
January 17th 2025In an interview with Peers & Perspectives in Oncology, Michael S. Leapman, MD, MHS, discusses the significance of a 10-year rise in active surveillance and watchful waiting in patients with intermediate-risk prostate cancer.
Read More
